Skip to contentpdufa.bio

ERAS-4001 (pan-KRAS inhibitor)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ERAS-4001 (pan-KRAS inhibitor) is an Erasca, Inc. program. Its next catalyst is a Readout in Q4 2026.

ERAS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Erasca, Inc. (ERAS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026ERAS

Specialist biotech funds holding ERAS, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RTW Investments22,446,754$329.1 millionfiled November 16, 2026
Cormorant Asset Management5,000,000$73.3 millionfiled November 16, 2026
EcoR1 Capital2,950,000$43.2 millionfiled November 16, 2026
OrbiMed Advisors806,000$11.8 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is ERAS-4001 (pan-KRAS inhibitor)'s next FDA decision or readout?

The next tracked catalyst for ERAS-4001 (pan-KRAS inhibitor) is a Readout in Q4 2026.

What happened at ERAS-4001 (pan-KRAS inhibitor)'s most recent FDA decision?

No FDA decision for ERAS-4001 (pan-KRAS inhibitor) is in our archive yet.

Who makes ERAS-4001 (pan-KRAS inhibitor)?

Erasca, Inc. (ERAS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.